- cafead Jul 25, 2024 at 11:12: AM
via San Diego biotechnology company Autobahn Therapeutics on Wednesday said it raised $100 million to advance an experimental mood disorder medicine into mid-stage testing.
The company, which launched in 2020, is developing the drug for major depressive disorder and bipolar disorder depression.
article source
The company, which launched in 2020, is developing the drug for major depressive disorder and bipolar disorder depression.
article source